Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
about
Burden of illness of rheumatoid arthritis in Latin America: a regional perspectivePharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis.Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation--an economic analysis based on the ESPOIR cohort.The impact of the patient-centered medical home on the biologics industry, employers, and third-party payers.Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelHealth care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.Costs of moderate to severe chronic pain in primary care patients - a study of the ACCORD ProgramThe loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsApplying evidence in the care of patients with rheumatoid hand and wrist deformities.Current concepts in the management of the rheumatoid hand.Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitisIncremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data.Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patientsPredicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking.Location specific radiographic joint space width for osteoarthritis progression.Health economics: implications for novel antirheumatic therapies.Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatmentRheumatoid hand surgery: is there a decline? A 22-year population-based study.Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects.Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era.Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid ArthritisA 5-Year Cost-Effectiveness Analysis of Silicone Metacarpophalangeal Arthroplasty in Patients with Rheumatoid Arthritis.Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.Trends in out-of-pocket medical care expenditures for Medicare-age adults with arthritis between 1998 and 2004The impact of rheumatoid arthritis and biologics on employers and payers.Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs.Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs.Patient involvement in the development of a handbook for moderate rheumatoid arthritis.RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
P2860
Q26798332-18AD1458-DC80-4E65-AD90-C02E02896B6FQ31118397-0BDB6F82-B8BA-41E5-83DD-86D7D9DCA212Q33452656-84B4B4D2-FD6B-4C01-BF2B-21D95760C2BBQ33572753-F410A148-C243-4927-A04F-37DE730FEA58Q33584199-E66E43B0-AD2D-49FE-B504-B51E1902B06AQ33629056-4E40E4BC-8B3C-49F2-8689-E99C684E8A18Q33637603-F6B58FD7-3EA0-4A7E-988B-8AD0279F7328Q33717053-3FDDEC7C-7F36-4F74-B5BF-57E5304F0929Q33740641-98B51A9B-E6B0-4A56-B464-146007ABD733Q33871768-48A2C163-873F-47B7-B63C-85585F075F46Q33890193-D2CB2740-19FF-4866-ABE6-5E830BB9E784Q33923245-FE6B616F-C54E-4544-AE8E-D9623A300249Q33962865-46EC6A36-85DA-42D8-9C48-B08008DCE264Q34079091-24018EA0-C727-4DD6-B88B-DCFE28F349BAQ34110066-F31523A2-B7D4-4DA0-9025-68C0381B34C8Q34149534-CC2C14FC-72EB-428A-9179-151030A21A22Q34175681-E2B773BE-FF52-459A-8F95-D95DA803728DQ34192955-396A7947-6A62-4E33-B2B0-B876CA14E2D8Q34311262-C484596F-116F-46C3-808E-9D0B8D701861Q34618811-57756E6C-A832-419A-AABB-906F86C4E05DQ34998359-9C8677CA-65C7-4C96-B76D-5CA1F34FC7BFQ35110433-CAD67A8D-7A3D-447C-866C-C23FB8ED2BAAQ35579507-2474C2A8-C9A7-47A1-B58A-558BC4C9FD68Q35637812-AEC9EA4F-40F9-4BEC-AFAA-4D66BB522CB0Q35661467-DBC57951-53CA-4B0B-950A-5D0E402AFE16Q35840805-EBC09D62-F366-4E6E-825E-F7C6C49F3314Q36197850-96E8B51D-1244-4066-84D4-DCC5011BD12FQ36475642-D980FBD9-437B-4222-9507-06EA097887CFQ36480601-5209BD38-97FF-4701-AD34-5CDB1C716FEAQ36720944-26BB3E35-4AA2-43F6-9DAF-BBEC238B37FAQ37000165-9D38CE82-6FB0-4FDE-8CCF-C7DDF19F6B8EQ37247415-A7F22587-8B7D-4B66-B722-046C2FEF4DBAQ37251489-789B502D-71B4-41C7-8FBE-A1912D203657Q37471597-1F6D032D-7034-4FED-8A00-B6C38F1D5925Q37609399-6B1C9209-FCB2-4B84-AA53-6ABA113FD7BEQ37613103-DB0EA075-7837-4C0B-8607-4ECDD5FD2225Q37691184-0C7740E2-6F98-4E5B-AED3-B8772E4F4196Q37705127-ABB0E338-6235-4500-8276-64579E0965FFQ37786625-9815851A-6627-4C1A-AD5D-E946EDDA4DE0Q37803416-9BE21370-B36F-446D-8818-8BD4008376B1
P2860
Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Direct medical costs and their ...... -year study of 7,527 patients.
@en
Direct medical costs and their ...... -year study of 7,527 patients.
@nl
type
label
Direct medical costs and their ...... -year study of 7,527 patients.
@en
Direct medical costs and their ...... -year study of 7,527 patients.
@nl
prefLabel
Direct medical costs and their ...... -year study of 7,527 patients.
@en
Direct medical costs and their ...... -year study of 7,527 patients.
@nl
P2093
P2860
P356
P1476
Direct medical costs and their ...... -year study of 7,527 patients.
@en
P2093
Hyon K Choi
Jodi Messer
Kaleb Michaud
P2860
P304
P356
10.1002/ART.11439
P577
2003-10-01T00:00:00Z